NeuroDerm Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
22 déc. 2016 09h43 HE
|
NeuroDerm Ltd.
REHOVOT, Israel, Dec. 22, 2016 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (NASDAQ:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced...
NeuroDerm Announces Completion of Patient Enrollment and Treatment in a Phase II Trial of ND0612H for Advanced Parkinson’s Disease
22 déc. 2016 07h00 HE
|
NeuroDerm Ltd.
- First evaluation of clinical efficacy of ND0612H in advanced Parkinson's patients -REHOVOT, Israel, Dec. 22, 2016 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage...
NeuroDerm Announces Closing of a Follow-On Offering of Ordinary Shares
12 déc. 2016 10h38 HE
|
NeuroDerm Ltd.
REHOVOT, Israel, Dec. 12, 2016 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (NASDAQ:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced...
NeuroDerm Announces Pricing of a Follow-On Offering of Ordinary Shares
07 déc. 2016 08h50 HE
|
NeuroDerm Ltd.
REHOVOT, Israel, Dec. 07, 2016 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (NASDAQ:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced...
NeuroDerm Announces Launch of a Follow-On Offering of Ordinary Shares
06 déc. 2016 16h14 HE
|
NeuroDerm Ltd.
REHOVOT, Israel, Dec. 06, 2016 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (NASDAQ:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced...
NeuroDerm to Replace Two Phase 3 Clinical Trials with Small Pharmacokinetic Trials Following FDA Meeting on ND0612 Regulatory Development
05 déc. 2016 06h30 HE
|
NeuroDerm Ltd.
- Company to pursue comparative bioavailability regulatory route instead of clinical efficacy development route -- NeuroDerm to add patients to its long-term safety trial -- Conference call and...
NeuroDerm Announces Top-Line Results of Pilot PK Trial Comparing ND0701 with Commercial Apomorphine
02 déc. 2016 07h00 HE
|
NeuroDerm Ltd.
REHOVOT, Israel, Dec. 02, 2016 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical Company developing drugs for central nervous system (CNS) disorders, today...
NeuroDerm Announces Third Quarter 2016 Financial Results
10 nov. 2016 07h00 HE
|
NeuroDerm Ltd.
REHOVOT, Israel, Nov. 10, 2016 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced...
NeuroDerm CEO to Present at Upcoming Investor Conferences
03 nov. 2016 07h00 HE
|
NeuroDerm Ltd.
REHOVOT, Israel, Nov. 03, 2016 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced...
NeuroDerm to Host Third Quarter 2016 Financial Results Conference Call on November 10, 2016
01 nov. 2016 07h00 HE
|
NeuroDerm Ltd.
REHOVOT, Israel, Nov. 01, 2016 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced...